Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Silo Pharma, Inc. Director's Dealing 2023

May 26, 2023

35304_dirs_2023-05-26_d153a9ec-5169-4591-8b1a-39648f81300e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Silo Pharma, Inc. (SILO)
CIK: 0001514183
Period of Report: 2023-05-26

Reporting Person: Ryweck Daniel E. (Chief Financial Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-05-26 Common Stock P 1000 $2.1264 Acquired 5000 Direct